- European Biotech Investor Day in NYC, New York, USA
- The Alzheimer’s Association International Conference AAIC- 2018 – Chicago, USA
MADRID, Spain and CAMBRIDGE, Mass., July 02, 2018 (GLOBE NEWSWIRE) — Oryzon Genomics (ISIN Code: ES0167733015) (BME:ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today that Executive Directors of the company will present at several international reputed conferences in July.
Dr. Carlos Buesa, Oryzon’s CEO, will present the company at the European Biotech Investor Day in NYC organized by Goodwin LLC, Solebury Trout and NASDAQ. The Conference will be held at Goodwin LLC Offices in the New York Times Building on July 19th.
In addition, Dr. Roger Bullock, Oryzon’s Medical Director and Dr. Buesa will attend the Alzheimer’s Association International Conference AAIC-2018 to be held on July 22-26 in Chicago at the McCormick Convention Center. The Alzheimer’s Association International Conference is the largest and most influential international meeting dedicated to advancing dementia science and this year will bring together leaders from more than 70 countries to network and discuss the latest dementia study results and theories.
The company has accelerated its clinical developments by starting recently a second Phase IIa clinical trial with ORY-2001, in mild and moderate Alzheimer’s patients after receiving the authorizations from the regulatory authorities of Spain, France and the United Kingdom. The company is also running a Phase IIa clinical trial with ORY-2001 in multiple sclerosis patients. ORY-2001 is an oral, brain penetrant drug that selectively inhibits LSD1 and MAOB. The molecule acts at several levels, reducing cognitive deterioration, memory loss and neuroinflammation, and at the same time has shown neuroprotective effects. Epigenetic approaches, which produce changes in the patterns of gene expression in brain cells, can play an important role in neurodegenerative and psychiatric disorders.
Furthermore, the company has also an oncology program, ORY-1001, in Phase IIa in acute myeloid leukemia and small cell lung cancer. Recently, links between I-O and LSD1 have been reported, broadening even more LSD1 clinical potential.
Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field. Oryzon’s LSD1 program has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. The company has offices in Spain and USA. For more information, visit www.oryzon.com.
This communication contains forward-looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates” and similar expressions. Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the Comisión Nacional del Mercado de Valores, which are accessible to the public. Forward-looking statements are not guarantees of future performance. The auditors of Oryzon Genomics, S.A, have not reviewed them. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof. Except as required by applicable law, Oryzon Genomics, S.A. does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States. The Company’s securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of the Company’s securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company or the selling security holder, as applicable, that will contain detailed information about the Company and management, as well as financial statements.
|US Contact:||Spain:||The Company:|
|The Trout Group||ATREVIA||Emili Torrell|
|Thomas Hoffmann||Patricia Cobo/Luis Rejano||BD Director|
|+1 646 378 2932||+34 91 564 07 25||+34 93 515 13 13|